In the Claims:

Please cancel claims 1-43 without prejudice.

Please amend the claims to read as follows:

1.-43. (Canceled)

44. (New) A composition comprising an activator of NKT cells and a TLR activator in a pharmaceutically acceptable carrier, wherein when the activator of NKT cells is a glycosylceramide then the TLR activator is not CpG or MPL.

45. (New) The composition of claim 44, wherein the activator of NKT cells is α-GalCer or OCH or both.

46. (New) The composition of claim 44, wherein the activator of TLR is a member selected from the group consisting of TLR3, TLR4, TLR5, TLR7 and TLR9.

47. (New) The composition of claim 46, wherein the TLR is TLR4 and the activator is MPL.

48. (New) The composition of claim 44, wherein the activator of NKT cells is α-GalCer or α-glucosyl ceramide the activator of TLR is MPL or CpG.

49. (New) The composition of claim 44, further comprising a purified soluble polypeptide antigen.

50. (New) The composition of claim 49, wherein said antigen is a member selected from the group consisting of a tumor antigen, a viral antigen and a bacterial antigen.

51. (New) The composition of claim 44, wherein said pharmaceitically acceptable carrier is a liposome.

52. (New) A method for inducing an immune response in an individual, comprising administering to said individual an effective amount of the composition of claim 44.

53. (New) A method for inducing an immune response against a soluble polypeptide antigen in an individual, comprising administering to said individual and effective amount of an activator of NKT cells and a soluble polypeptide antigen, wherein when the activator of NKT cells is a glycosylceramide then the TLR activator is not CpG or MPL.

54. (New) The method of claim 53, further comprising administering a TLR activator.

55. (New) The method of claim 53, wherein the activator of NKT cells is α-GalCer or OCH or both.

56. (New) The method of claim 53, wherein the activator of TLR is a member selected from the group consisting of TLR3, TLR4, TLR5, TLR7 and TLR9.

57. (New) The method of claim 53, wherein the activator of NKT cells is administered about 2 hours before administering the polypeptide antigen.

58. (New) The method of claim 53, wherein the activator of NKT cells is administered within about 8 hours after administering the polypeptide antigen.

59. (New) The method of claim 53, wherein the activator of NKT cells is administered concurrently with the polypeptide antigen.

60. (New) The method of claim 53, wherein the polypeptide antigen is a member selected from the group consisting of a tumor antigen, a viral antigen and a bacterial antigen.

61. (New) The method of claim 53, wherein the activator of NKT cells is OCH.

62. (New) The method of claim 54, wherein the activator of NKT cells is OCH.

63. (New) The method of claim 57, wherein the activator of NKT cells is OCH.

64. (New) The method of claim 58, wherein the activator of NKT cells is OCH.

65. (New) The method of claim 59, wherein the activator of NKT cells is OCH.

66. (New) The method of claim 53, wherein the activator of NKT cells is α-GalCer or α-glucosylceramide.

67. (New) The method of claim 54, wherein the activator of NKT cells is α-GalCer or α-glucosylceramide.

68. (New) The method of claim 67, wherein the TLR activator is CpG or MPL or both.

69. (New) A kit comprising first and second containers, wherein the first container comprises a composition comprising an activator of NKT cells and the second container comprises a composition comprising a TLR activator, wherein when the activator of NKT cells is a glycosylceramide then the TLR activator is not CpG or MPL.

70. (New) The kit of claim 69, further comprising a third container comprising a purified polypeptide antigen.